News &amp; Updates

Tirzepatide proves safety, efficacy in T1D in real world

09 Oct 2025 by

The use of tirzepatide in a real-world setting demonstrates a favourable safety profile and results in weight loss, lower insulin requirements, and better glycaemic measurements among patients with type 1 diabetes (T1D), as shown in a study presented at EASD 2025.

Tirzepatide proves safety, efficacy in T1D in real world

09 Oct 2025

Does anticoagulant use improve survival in PAH?

The use of anticoagulant therapy offers no survival benefit in patients with pulmonary arterial hypertension (PAH), a recent study has shown.

Does anticoagulant use improve survival in PAH?

PPIs unlikely linked to increased stroke risk in patients taking antithrombotics

09 Oct 2025 by

Researchers at the University of Hong Kong (HKU) have found that the risk of ischaemic stroke is not increased in patients on proton-pump inhibitor (PPI) monotherapy, but is increased in those coprescribed with antithrombotic drugs, possibly due to their underlying higher risk profiles.

PPIs unlikely linked to increased stroke risk in patients taking antithrombotics

Old drug, new purpose: Low-dose ATG may halt T1D progression in youths

08 Oct 2025 by

The old immunomodulatory drug antithymocyte globulin (ATG), administered at a low dose, can safely reduce the loss of beta-cell function in young people with recent-onset type 1 diabetes (T1D), as shown in the phase II MELD-ATG trial.

Old drug, new purpose: Low-dose ATG may halt T1D progression in youths

Liver-directed RT plus atezolizumab-bevacizumab improves response rates in HCC patients

Adding liver-directed radiation therapy (RT) to atezolizumab and bevacizumab (A/B) produces limited additional toxicity with higher response rates among patients with hepatocellular carcinoma (HCC), reports a recent study. However, substantial differences in baseline characteristics hinder a full interpretation of this data.

Liver-directed RT plus atezolizumab-bevacizumab improves response rates in HCC patients

Antioxidant supplementation in men seeking fertility care does not improve pregnancy rates

The use of antioxidant supplements in men seeking fertility care does not appear to increase the chances of conceiving for their female partners, as shown in the multicentre SUMMER trial.

Antioxidant supplementation in men seeking fertility care does not improve pregnancy rates

Infliximab superior to adalimumab in bio-naïve patients with FCD

A recent study has shown infliximab’s superiority over adalimumab in the treatment of bio-naïve patients with fistulizing Crohn’s disease (FCD). However, there is no therapeutic difference seen in bio-exposed FCD.

Infliximab superior to adalimumab in bio-naïve patients with FCD

Ritlecitinib efficacy sustained up to 3 years in ALLEGRO trials

07 Oct 2025 by

Ritlecitinib 50 mg demonstrates clinically meaningful efficacy up to 36 months in individuals with alopecia areata (AA) in the phase IIb/III ALLEGRO and ongoing phase III ALLEGRO-LT trials.

Ritlecitinib efficacy sustained up to 3 years in ALLEGRO trials

07 Oct 2025

Novel cannabinoid receptor 1 inverse agonist a promising medication for obesity

Treatment with the novel cannabinoid receptor 1 (CB1R) inverse agonist monlunabant appears to yield significant and clinically meaningful weight loss in adults with obesity and metabolic syndrome, according to a phase IIa trial.

Novel cannabinoid receptor 1 inverse agonist a promising medication for obesity